Abstract:In the 1960s, through laboratory-based investigations of peripheral blood partnered with detailed clinical annotations, Dr. Waldenström described a condition he called "benign monoclonal gammopathy". These patients were asymptomatic with a detectable monoclonal protein, and did not meet imaging and laboratory criteria for multiple myeloma. In 1978, through observational retrospective review of medical records, Dr. Kyle observed that not all cases of monoclonal gammopathy were benign. He introduced the term monoclonal gammopathy of undetermined significance (MGUS) to describe a condition that may potentially progress to multiple myeloma (MM), highlighting clinical inability in predicting which patients might progress. In 1980, Drs. Kyle and Greipp described 6 cases which did not fit the definitions of MGUS or MM, and they remained asymptomatic after at least 5 years of follow-up; they were proposed to have smoldering multiple myeloma (SMM). Over time, SMM was defined by arbitrary numerical values (≥10 % plasma cells in the bone marrow and serum M-protein concentration ≥ 3 g/dl). Numerous clinical scores have been developed to define high-risk groups for progression to MM. Current statistical models for progression provide only average risk scores, offering limited clinical utility since the risk of progression at an individual level remains unknown. Physician-scientists are focusing on emerging technologies, such as whole genome sequencing, tumor microenvironment analysis, and single-cell RNA sequencing, to understand precursor states at a molecular level. The overarching goal of these technologies is to better characterize monoclonal gammopathy and other myeloma precursor states. This will enable clinicians to provide more precise, individualized risk assessments and ultimately improve patient outcomes. This review outlines the history of MM precursor states, current definitions, challenges in risk stratification models, and the role of emerging technologies in enhancing predictions and outcomes.

Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer

Smoldering multiple myeloma current treatment algorithms

Smoldering Multiple Myeloma: Observation Versus Control Versus Cure

Smoldering Multiple Myeloma : Taking the narrow over the wide path?

Mode of progression in smoldering multiple myeloma: a study of 406 patients

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)

Evaluating early intervention in smoldering myeloma clinical trials: a systematic review

Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper

An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities

How to Identify and Manage High-Risk Smoldering Multiple Myeloma

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

The Difficulty in Defining the True High-Risk Smoldering Myeloma

From MGUS to multiple myeloma: Unraveling the unknown of precursor states

Multiple myeloma, immunotherapy and minimal residual disease

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

New diagnostic strategy for multiple myeloma: A review

Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics